Lung disease diagnostics firm Biodesix improved results in Q1
LOUISVILLE — Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung disease, boosted its year-over-year top and bottom line performance in the first quarter of 2024.
The company posted revenue of $14.8 million in the most recent period, an increase of 64% compared to the first quarter of 2023.
Biodesix’s net loss was $13.6 million in the first quarter of this year, a 27% improvement over its first quarter 2023 results.
SPONSORED CONTENT
Commercial Solar is a big investment, but not an overwhelming one
Solar offers a significant economic benefit for commercial property owners while also positively impacting the environment and offering a path to compliance for new municipal requirements like Energize Denver. A local, experienced solar installer will help you navigate the complexities of commercial solar to achieve financial success for your project.
“I am very pleased to announce yet another quarter of greater than 50% revenue and volume growth and 14 percentage point improvement in gross margins,” Biodesix CEO Scott Hutton said in a prepared statement. “This is a year of execution with three main goals: growing top line revenue, implementing operational efficiencies while maintaining cost discipline, and making significant progress on our path to profitability.”
During the most recent quarter, Biodesix inked a collaborative research agreement with Memorial Sloan Kettering Cancer Center to co-develop cancer diagnostic tests and raised $55 million through a stock sale.
Looking ahead, Biodesix predicts full-year 2024 sales to range between $65 million and $68 million.